<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303963</url>
  </required_header>
  <id_info>
    <org_study_id>DRIA2014-326</org_study_id>
    <nct_id>NCT03303963</nct_id>
  </id_info>
  <brief_title>DIAgnostics for Multidrug Resistant Tuberculosis in Africa</brief_title>
  <acronym>DIAMA</acronym>
  <official_title>Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dissou AFFOLABI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rwanda Biomedical Center (RBC), Kigali, Rwanda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Tuberculosis Reference Laboratory Bamenda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale (INRB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jimma University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Service de Pneumophtisiologie, Hôpital Ignace Deen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Sciences, Techniques and Technologies of Bamako</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Damien Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheikh Anta Diop University, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genoscreen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoire de Référence des Mycobactéries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert
      Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin
      Resistant Tuberculosis (RR-TB) but only rifampicin resistance is diagnosed, leading to
      presumptive diagnosis of resistance to isoniazid and maybe other drugs. Thus in low and
      middle income countries, most drug sensitivity testing relies on phenotypic drug resistance
      testing, which takes up to 4 months. In addition, currently, culture on monthly sputum
      samples is recommended by the World Health Organization for follow-up of Rifampicin Resistant
      Tuberculosis patients under treatment. Unfortunately, culture is often not locally available
      and samples need to be transported from field to culture laboratories. The associated
      transport delays lead to high rates of contamination and false negative culture, particularly
      in laboratories in low resource settings. Many gaps for the diagnosis and management of RR-TB
      patients still need to be addressed and the DIAMA project (DIAgnostics for Multidrug
      resistant tuberculosis in Africa) study aims to address some of them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed DIAMA (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to
      address current gaps in the diagnosis and management of patients with Multi-Drug-Resistant
      (MDR) tuberculosis. Building on existing networks and research collaborations previously
      funded by the European &amp; Developing Countries Clinical Trials Partnership (EDCTP), this
      project involved partners in West, Central, and East Africa. It aims to evaluate and
      implement rapid and accurate molecular tests for several anti Tuberculosis drugs, to replace
      the current dependency on phenotypic drug resistance testing, which takes up to 4 months and
      is technically so demanding that few laboratories can perform it correctly.

      The project builds on the continuous surveillance of Tuberculosis retreatment patients for
      rifampicin resistance. Two African partners (Benin and Rwanda) with advanced molecular
      laboratories are establishing reference laboratories for the 'Deeplex' assay, a novel
      multiplex deep sequencing-based drug resistance diagnostic platform that simultaneously
      provides sequence information of genes that confer resistance to several key anti
      tuberculosis drugs. Partners are recruiting all patients with rifampicin resistant
      Tuberculosis, and a subset of those with rifampicin sensitive Tuberculosis. In a first phase,
      sputum will be shipped for the Deeplex assay, for comparison against phenotypic Drug
      Susceptibility Testing (DST), the reference method for detecting resistance to 1st and 2nd
      line anti-Tuberculosis drugs. In a second phase, InSilixa and Cepheid 2nd line GeneXpert, two
      'lower tech' tests at the last stages of laboratory validations, will be implemented in all
      countries that have established recruitment of retreatment patients. The InSilixa lab-on-chip
      assay, powered by a smartphone, is able to query 117 drug resistance conferring mutations at
      around $20 per test. The Cepheid GeneXpert 2nd line cartridge can be implemented in existing
      GeneXpert machines used for the GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/Rif)
      assays. These two tests will be compared versus the Deeplex assay.

      Using the latest advances in DataTocare software developed by one of the project partners,
      molecular results will be communicated in real time to the National Tuberculosis Programmes,
      so that Multi Drug Resistant Tuberculosis patients can swiftly start appropriate treatment.
      The added-value of this system will be evaluated as a pilot study in some sites.

      Lastly, once patients have initiated MDR treatment, they will be monitored for treatment
      success by faster alternative approaches to the World Health Organization recommended monthly
      cultures: serial sputum samples will have Fluorescein DiAcetate vital stain microscopy and
      measurement of the bacterial load using the GeneXpert MTB/Rif. Together, these advances are
      expected to dramatically improve the currently dismal prognosis of MDR patients in health
      systems in resource-poor settings.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of Deeplex test</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between phenotypic Drug Susceptibility Test and Deeplex results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of GeneXpert 2nd line</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Deeplex results and GeneXpert 2nd line results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of InSilixa chip assay</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Deeplex results and InSilixa chip assay results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of FDA microscopy</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Culture results and FDA microscopy results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of GeneXpert Ct value</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Culture results and GeneXpert Ct value results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of proportion of additional resistance in patients resistant to Rifampicin</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation to be done with the Deeplex test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the association of specific mutations against some drugs with programmatic treatment outcome</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation to be done with the Deeplex test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the add value of Connectivity system in the management of Multi Drug Resistant-Tuberculosis patients</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation to be done with Data2Care connectivity system</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2840</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Rifampicin resistant and susceptible patients</arm_group_label>
    <description>Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin resistant patients</arm_group_label>
    <description>Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Deeplex test, InSilixa chip assay, GeneXpert 2nd line</intervention_name>
    <description>Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:
Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)
Validating the InSilixa chip-based detection of resistance as a point of care test (Study 1 - phase 2)
Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)</description>
    <arm_group_label>Rifampicin resistant and susceptible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value</intervention_name>
    <description>Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:
FDA microscopy
Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin</description>
    <arm_group_label>Rifampicin resistant patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum.

      At the enrôlment, three samples (spot-overnight-spot) will be collected for the comparison of
      phenotypic results against molecular results.

      During the treatment, two monthly samples (overnight-spot) will be collected for the
      comparison of culture result against FDA Microscopy and GeneXpert Ct values.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Two multi center observational studies will be conducted:

        Study 1: Cross sectional study for Tuberculosis(TB) cases aged ≥ 15 (all Rifampicin
        resistant (RR) ones (new cases or retreatment patients) and equal number of Rifampicin
        sensitive retreatment patients from the same country) with comparison of TB resistance
        diagnostic test performance at baseline. There are 2 phases in this project; phase 1 is the
        comparison of Deeplex results against the phenotypic results (Gold standard), phase 2 is
        the comparison of Insilixa and GeneXpert 2nd generation results against Deeplex (gold
        standard).

        Study 2: Cohort study of RR-TB patients (recruited in Study 1) under treatment with
        comparison of the performance of FDA and GeneXpert compared to solid culture
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Being ≥ 15 year old

          -  Having a positive test on GeneXpert (M. tuberculosis) with or without resistance
             detected to rifampicin

          -  Willing and able to provide written informed consent, or for minors: assent from and
             consent from a legal representative

        Exclusion Criteria: None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dissou AFFOLABI, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de Référence des Mycobactéries</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dissou AFFOLABI, MD, MSc, PhD</last_name>
    <phone>66614862</phone>
    <phone_ext>00229</phone_ext>
    <email>affolabi_dissou@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Faridath MASSOU, PharmD</last_name>
    <phone>67244944</phone>
    <phone_ext>00229</phone_ext>
    <email>abenimas@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Tropical Medecine</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou</name>
      <address>
        <city>Cotonou</city>
        <state>Atlantique/Littoral</state>
        <zip>01BP321</zip>
        <country>Benin</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dissou AFFOLABI, MD PhD Prof</last_name>
      <phone>66614862</phone>
      <phone_ext>00229</phone_ext>
      <email>affolabi_dissou@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Faridath MASSOU, PharmD</last_name>
      <phone>67244944</phone>
      <phone_ext>00229</phone_ext>
      <email>abenimas@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Tuberculosis Reference Laboratory Bamenda</name>
      <address>
        <city>Bamenda</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa SANDER, MSc, PhD</last_name>
      <phone>694721484</phone>
      <phone_ext>00237</phone_ext>
      <email>melissa.sander@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut National de Recherche Biomédicale (INRB)</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel KASWA, MD MSc MPH</last_name>
      <phone>999928694</phone>
      <phone_ext>00243</phone_ext>
      <email>meckkay2002@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jimma University</name>
      <address>
        <city>Jīma</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gemeda Ayana ABEBE, MSc PhD Associate Prof</last_name>
      <phone>911991285</phone>
      <phone_ext>00251</phone_ext>
      <email>Gemeda.abebe@ju.edu.et</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Pneumophtisiologie, Hôpital Ignace Deen, Conakry</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oumou Younoussa BAH-SOW, MD, Prof</last_name>
      <phone>664962434</phone>
      <phone_ext>00224</phone_ext>
      <email>oumou45@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université des Sciences, des Techniques et des Technologies de Bamako, SEREFO</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassirou DIARRA, MD MSc PhD Student</last_name>
      <phone>66807491</phone>
      <phone_ext>00223</phone_ext>
      <email>bdiarra@icermali.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Damien Fundation</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Othman EL TAYEB, BSc MSc</last_name>
      <phone>8023683356</phone>
      <phone_ext>00234</phone_ext>
      <email>osman.eltayeb@dfbnigeria.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rwanda Biomedical Center (RBC)</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude SEMUTO NGABONZIZA, MSc PhD student</last_name>
      <phone>788740490</phone>
      <phone_ext>00250</phone_ext>
      <email>cldsemuto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université Cheick Anta Diop (UCAD)</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aïssatou GAYE-DIALLO, PharmD Prof</last_name>
      <phone>338225919</phone>
      <phone_ext>00221</phone_ext>
      <email>ayougayediallo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Benin</country>
    <country>Cameroon</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Ethiopia</country>
    <country>Guinea</country>
    <country>Mali</country>
    <country>Nigeria</country>
    <country>Rwanda</country>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.</citation>
    <PMID>20825313</PMID>
  </reference>
  <results_reference>
    <citation>Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.</citation>
    <PMID>25097082</PMID>
  </results_reference>
  <results_reference>
    <citation>Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.</citation>
    <PMID>25216831</PMID>
  </results_reference>
  <results_reference>
    <citation>Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94. doi: 10.5588/ijtld.13.0075.</citation>
    <PMID>25216832</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. Epub 2010 May 4.</citation>
    <PMID>20442432</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2017</study_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Laboratoire de Référence des Mycobactéries</investigator_affiliation>
    <investigator_full_name>Dissou AFFOLABI</investigator_full_name>
    <investigator_title>Professor (Deputy Head of the Laboratory)</investigator_title>
  </responsible_party>
  <keyword>culture-free</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>multidrug resistant</keyword>
  <keyword>diagnosis</keyword>
  <keyword>follow-up</keyword>
  <keyword>africa</keyword>
  <keyword>molecular tools</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

